Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


10 Items
Title  Creator  Group name  Publishing year 
Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results Bascoul-Mollevi et al. EquipeCTCS 2021-01
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative Cohen et al. EquipeMY 05/2020
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial André et al. EquipeMY May 20, 2018
The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers Mariette et al. EquipeMY 02 06, 2018
Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD Bascoul-Mollevi et al. EquipeMY May 2018
Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review Ousmen et al. EquipeMY Dec 11, 2018
Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial Barbieri et al. EquipeMY 07 2016
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB] Ezzalfani et al. EquipeMY Jan 2015
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Anota et al. EquipeMY Jan 2015
Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Guiu et al. EquipeCTCS Dec 2014
10 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés